Scancell Holdings Plc
| London Stock Exchange: SCLP
Scancell Holdings Plc is a biopharmaceutical company, which develops novel therapeutic vaccines for the treatment of cancer and infectious diseases. The company's clinical candidate drug cancer vaccine SCIB1 is a plasmid DNA, which encodes a human antibody molecule engineered to express a melanoma antigen called Tyrosinase-Related Protein 2 plus two helper T cell epitopes. Scancell Holdings founded by Lindy Gillian Durrant in 1997 and is headquartered in Nottingham, the United Kingdom.